EMA positive opinion for orphan drug designation to Camurus’ octreotide SC depot for the treatment of polycystic liver disease
Lund, Sweden — 20 September 2024 — Camurus (NASDAQ STO: CAMX) today announced that the Committee for Orphan Medicinal Products (COMP) at the European Medicines Agency (EMA) has adopted a positive opinion for orphan drug designation (ODD) to the company’s investigational medicinal product, octreotide subcutaneous (SC) depot (CAM2029), for the treatment of autosomal dominant polycystic liver disease (PLD). The European Commission is now assessing the opinion and is expected to grant the designation within 30 days. PLD is a rare, genetic, and chronic disorder characterized by progressive